FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313454989> ?p ?o ?g. }

• W4313454989 abstract "Abstract Background Febrile neutropenia (FN) is a prevalent and potentially life-threatening complication in patients with lymphoma receiving myelosuppressive chemotherapy. Pegfilgrastim is more effective than filgrastim as prophylaxis for FN. However, its usage has been limited because of its higher cost. Pegfilgrastim’s value for money remains unclear. Objective To systematically review the cost-effectiveness of pegfilgrastim compared to filgrastim as a primary or secondary prophylaxis for chemotherapy-induced FN among patients with lymphoma. Methods A systematic literature search was conducted in PubMed, EMBASE, Cochrane Library databases, and Google Scholar. The most widely used economic evaluations (cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis) were included in the review. Data extraction was guided by the Consolidated Health Economic Evaluation Reporting Standards checklist, and the quality of reviewed articles was assessed using the Joanna Briggs Institute (JBI) checklist. Cost-effectiveness data were rigorously summarized and synthesized narratively. Costs were adjusted to US$ 2020. Results We identified eight economic evaluation studies (two cost-utility analyses, three cost-effectiveness analyses, and three studies reporting both cost-effectiveness and cost-utility analyses). Half of these studies were from Europe ( n = 4), the other half were from Iran, USA, Canada, and Singapore. Six studies met > 80% of the JBI quality assessment criteria. Cost-effectiveness estimates in the majority ( n = 6) of these studies were for Non-Hodgkin Lymphoma patients receiving myelosuppressive chemotherapy with high-risk of FN ( > 20%). The studies considered a wide range of baseline FN risk (17–97.4%) and mortality rates (5.8–8.9%). Reported incremental cost-effectiveness ratios ranged from US$ 2199 to US$ 8,871,600 per quality-adjusted life-year (QALY) gained, dominant to US$ 44,358 per FN averted, and US$ 4261- US$ 7251 per life-years gained. The most influential parameters were medication and hospitalization costs, the relative risk of FN, and assumptions of mortality benefit. Conclusions Most studies showed that pegfilgrastim is cost-effective compared to filgrastim as primary and secondary prophylaxis for chemotherapy-induced FN among patients with lymphoma at a cost-effectiveness threshold of US$ 50,000 per QALY gained. The findings could assist clinicians and healthcare decision-makers to make informed decisions regarding resource allocation for the management of chemotherapy-induced FN in settings similar to those studied." @default.
• W4313454989 created "2023-01-06" @default.
• W4313454989 creator A5008650274 @default.
• W4313454989 creator A5012720469 @default.
• W4313454989 creator A5032844648 @default.
• W4313454989 creator A5040701844 @default.
• W4313454989 creator A5058782721 @default.
• W4313454989 date "2022-12-30" @default.
• W4313454989 modified "2023-10-09" @default.
• W4313454989 title "Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review" @default.
• W4313454989 cites W1530919096 @default.
• W4313454989 cites W1902863658 @default.
• W4313454989 cites W1973935677 @default.
• W4313454989 cites W1980384927 @default.
• W4313454989 cites W1990248717 @default.
• W4313454989 cites W1993608325 @default.
• W4313454989 cites W2024933507 @default.
• W4313454989 cites W2043790030 @default.
• W4313454989 cites W2053883514 @default.
• W4313454989 cites W2063608974 @default.
• W4313454989 cites W2076143652 @default.
• W4313454989 cites W2083336892 @default.
• W4313454989 cites W2110534467 @default.
• W4313454989 cites W2110631033 @default.
• W4313454989 cites W2110645520 @default.
• W4313454989 cites W2114201476 @default.
• W4313454989 cites W2124057396 @default.
• W4313454989 cites W2157182577 @default.
• W4313454989 cites W2157799421 @default.
• W4313454989 cites W2161374186 @default.
• W4313454989 cites W2171438287 @default.
• W4313454989 cites W2253931716 @default.
• W4313454989 cites W2341045926 @default.
• W4313454989 cites W2342881896 @default.
• W4313454989 cites W2513382862 @default.
• W4313454989 cites W2560692010 @default.
• W4313454989 cites W2735044683 @default.
• W4313454989 cites W3165272195 @default.
• W4313454989 cites W4206121490 @default.
• W4313454989 cites W4236993833 @default.
• W4313454989 doi "https://doi.org/10.1186/s12913-022-08933-z" @default.
• W4313454989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36585648" @default.
• W4313454989 hasPublicationYear "2022" @default.
• W4313454989 type Work @default.
• W4313454989 citedByCount "1" @default.
• W4313454989 countsByYear W43134549892023 @default.
• W4313454989 crossrefType "journal-article" @default.
• W4313454989 hasAuthorship W4313454989A5008650274 @default.
• W4313454989 hasAuthorship W4313454989A5012720469 @default.
• W4313454989 hasAuthorship W4313454989A5032844648 @default.
• W4313454989 hasAuthorship W4313454989A5040701844 @default.
• W4313454989 hasAuthorship W4313454989A5058782721 @default.
• W4313454989 hasBestOaLocation W43134549891 @default.
• W4313454989 hasConcept C112930515 @default.
• W4313454989 hasConcept C126322002 @default.
• W4313454989 hasConcept C143998085 @default.
• W4313454989 hasConcept C15744967 @default.
• W4313454989 hasConcept C168563851 @default.
• W4313454989 hasConcept C17744445 @default.
• W4313454989 hasConcept C177713679 @default.
• W4313454989 hasConcept C180747234 @default.
• W4313454989 hasConcept C189708586 @default.
• W4313454989 hasConcept C199539241 @default.
• W4313454989 hasConcept C2776478404 @default.
• W4313454989 hasConcept C2776694085 @default.
• W4313454989 hasConcept C2777063308 @default.
• W4313454989 hasConcept C2778658803 @default.
• W4313454989 hasConcept C2778850193 @default.
• W4313454989 hasConcept C2779171977 @default.
• W4313454989 hasConcept C2779356329 @default.
• W4313454989 hasConcept C2779473830 @default.
• W4313454989 hasConcept C3019080777 @default.
• W4313454989 hasConcept C71924100 @default.
• W4313454989 hasConceptScore W4313454989C112930515 @default.
• W4313454989 hasConceptScore W4313454989C126322002 @default.
• W4313454989 hasConceptScore W4313454989C143998085 @default.
• W4313454989 hasConceptScore W4313454989C15744967 @default.
• W4313454989 hasConceptScore W4313454989C168563851 @default.
• W4313454989 hasConceptScore W4313454989C17744445 @default.
• W4313454989 hasConceptScore W4313454989C177713679 @default.
• W4313454989 hasConceptScore W4313454989C180747234 @default.
• W4313454989 hasConceptScore W4313454989C189708586 @default.
• W4313454989 hasConceptScore W4313454989C199539241 @default.
• W4313454989 hasConceptScore W4313454989C2776478404 @default.
• W4313454989 hasConceptScore W4313454989C2776694085 @default.
• W4313454989 hasConceptScore W4313454989C2777063308 @default.
• W4313454989 hasConceptScore W4313454989C2778658803 @default.
• W4313454989 hasConceptScore W4313454989C2778850193 @default.
• W4313454989 hasConceptScore W4313454989C2779171977 @default.
• W4313454989 hasConceptScore W4313454989C2779356329 @default.
• W4313454989 hasConceptScore W4313454989C2779473830 @default.
• W4313454989 hasConceptScore W4313454989C3019080777 @default.
• W4313454989 hasConceptScore W4313454989C71924100 @default.
• W4313454989 hasIssue "1" @default.
• W4313454989 hasLocation W43134549891 @default.
• W4313454989 hasLocation W43134549892 @default.
• W4313454989 hasLocation W43134549893 @default.
• W4313454989 hasLocation W43134549894 @default.
• W4313454989 hasOpenAccess W4313454989 @default.
• W4313454989 hasPrimaryLocation W43134549891 @default.

• next